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Introduction
Central nervous system (CNS) metastases frequently occur 
in non-small cell lung cancer (NSCLC). Approximately 
10–20% of patients with NSCLC present with CNS 
metastases at diagnosis, and about 40–70% will develop 
CNS metastases during the course of their disease (1-3). 
CNS metastases are a poor prognostic factor and have a 
negative impact on quality of life (QoL) (4). 
Due to both increased screening for CNS metastases in 
almost all NSCLC disease stages [except the (very) early 
stages] (5-7), and improved NSCLC survival rates, the 
incidence of CNS metastases is increasing. Next to this, 
the detection of asymptomatic CNS metastases due to 
screening in otherwise non-metastatic patients can result 
in an increased incidence of CNS only metastases (7,8). 
The widespread uptake of magnetic resonance imaging 
(MRI, advised in current guidelines) instead of computed 
tomography (CT) for CNS metastases screening probably 
Central nervous system metastases and oligoprogression during 
treatment with tyrosine kinase inhibitors in oncogene-addicted 
non-small cell lung cancer: how to treat and when?
Janna Josephus Anna Oda Schoenmaekers1,2, Marthe Sentijna Paats3, Anne-Marie Clasina Dingemans1,2,3, 
Lizza Elisabeth Lucia Hendriks1,2
1Department of Pulmonary Diseases, Maastricht University Medical Centre, Maastricht, The Netherlands; 2Department of Pulmonary Diseases 
GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; 3Department of 
Pulmonary Diseases, Erasmus Medical Centre, Rotterdam, The Netherlands 
Contributions: (I) Conception and design: All Authors; (II) Administrative support: All Authors; (III) Provision of study materials or patients: All 
Authors; (IV) Collection and assembly of data: All Authors; (V) Data analysis and interpretation: All Authors; (VI) Manuscript writing: All authors; (VII) 
Final approval of manuscript: All authors.
Correspondence to: Prof. Anne-Marie Clasina Dingemans, MD, PhD. Department of Pulmonary Diseases, Erasmus Medical Centre, P.O. 2040, 3000 
CA Rotterdam, The Netherlands. Email: a.dingemans@erasmusmc.nl. 
Abstract: Up to 70% of non-small cell lung cancer (NSCLC) patients develop central nervous system 
(CNS) metastases during the course of their disease, especially those with oncogenic drivers treated with 
a first-generation tyrosine kinase inhibitor (TKI), because of the relatively poor CNS penetration. CNS 
metastases are associated with a negative impact on quality of life and survival. As, with the introduction 
of newer generation TKIs, the survival rates are increasing in this particular population, treatment and/
or prevention of CNS metastases becomes even more relevant and the TKI with the best CNS efficacy 
should be selected. Unfortunately, CNS efficacy data in clinical trials are not fully comparable. Furthermore, 
oligoprogression to the brain without extracranial progression regularly occurs in the oncogenic driver 
population and both local therapy and switch of systemic therapy are possible treatment options. However, 
the best order of systemic and local therapy is still not precisely known. In this narrative review, we will 
summarize incidence and treatment of CNS metastases in oncogene driven NSCLC, including the optimal 
treatment of CNS oligometastatic disease (synchronous as well as oligoprogressive).
Keywords: Non-small cell lung cancer (NSCLC); central nervous system metastases (CNS metastases); 
oligometastatic disease; tyrosine kinase inhibitors (TKIs)
Submitted Mar 20, 2020. Accepted for publication Jun 04, 2020.
doi: 10.21037/tlcr-20-459
View this article at: http://dx.doi.org/10.21037/tlcr-20-459
2617
Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions
2600 Schoenmaekers et al. CNS metastases and oligoprogression during TKI treatment
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2020;9(6):2599-2617 | http://dx.doi.org/10.21037/tlcr-20-459
results in an even higher incidence of CNS only metastases, 
as MRI is more sensitive than CT (9). A topic of discussion 
is the best sequence of treatments in patients with baseline 
asymptomatic CNS disease: local treatment (e.g., radiation) 
followed by systemic therapy, or systemic therapy with 
local treatment upon CNS progression (7,8,10,11). A 
special category are those patients with oncogenic driven 
NSCLC. In general, the preferred treatment option for 
neurologically asymptomatic oncogene-addicted NSCLC 
patients [epidermal growth factor receptor (EGFR) 
mutation, rearrangements of anaplastic-lymphoma-kinase 
(ALK), ROS proto-oncogene 1 (ROS1), MET deregulation 
(amplification or MET exon 14 mutations), RET-fusions, 
N tropomyosin receptor kinase (NTRK) gene fusion, B-Raf 
proto-oncogene (BRAFv600E) mutation] is a tyrosine 
kinase inhibitor (TKI) (5,7). An advantage of the next 
generation TKIs is the often superior CNS penetration rate 
compared with the first generation TKIs (12,13). As the 
median overall survival (OS) of patients with EGFR or ALK 
driven NSCLC has improved to more than 5 years it is 
expected that CNS metastases will become more prevalent 
in this group, and that patients will live longer with CNS 
metastases (14,15). Therefore, the optimal treatment, 
and preferably even prevention, of CNS metastases is an 
important topic in current clinical trials enrolling patients 
with oncogene-addicted NSCLC. Historically, patients 
with CNS metastases were often not eligible for trial 
participation. Although symptomatic brain metastases (BM) 
and leptomeningeal metastases (LM) are still exclusion 
criteria in the majority of clinical trials, patients with 
asymptomatic or treated BM are increasingly eligible (16). 
However, interpretation of CNS related outcome measures 
of clinical trials is hampered by the lack of standardisation 
of imaging in these trials (modality, frequency) and by 
the fact that BM eligibility criteria differ between trials 
(e.g., untreated allowed or not, definition of stable BM). 
Moreover, patients were not always stratified according to 
presence of BM, and outcome of this subgroup was rarely 
a prespecified endpoint (16). In addition, oligoprogression 
in the brain can occur during systemic treatment. Most 
trials did not specify which treatments were allowed while 
on study, and optimal therapy of CNS oligometastatic 
disease is largely unknown. This is especially relevant 
in patients with oncogene driven NSCLC who develop 
oligoprogressive disease in the brain, without extracranial 
progressive disease, while on TKI treatment. 
In this narrative review, we will summarize incidence and 
treatment of CNS metastases in oncogene driven NSCLC, 
including the optimal treatment of all types of CNS 
oligometastatic disease (e.g., synchronous, metachronous, 
oligopersistent, oligoprogressive). We will focus mainly on 
phase III trials, except when no phase III data are available 
or phase I/II data have added value (e.g., specific CNS 
subgroup data). 
The incidence of CNS metastases and TKI 
options in oncogene driven NSCLC patients
Oncogene-addicted NSCLC is characterized by a 
particularly high incidence of CNS metastases, with 
percentages reaching up to 70% for BM and 10% for LM 
during the course if the disease (1,17-21). 
EGFR mutation
The incidence of an activating EGFR mutation in lung 
cancer is about 10% in Caucasians and 50% in Asians (22). 
The incidence of BM at diagnosis ranges from 23–32% 
(19,23,24). In a retrospective series it was shown that 
with the use of first generation EGFR-TKI (erlotinib and 
gefitinib) and second generation EGFR-TKI (in this series 
only dacomitinib evaluated) the cumulative incidence of BM 
increases over time, resulting in a 5-year incidence of 53% 
(N=86 EGFR-mutated and 23 ALK-rearranged NSCLC 
patients) (19). 
Treatment options for metastatic EGFR-mutated 
NSCLC patients are first generation EGFR-TKI (erlotinib 
and gefitinib), second generation EGFR-TKI (afatinib, 
dacomitinib) and the third generation EGFR-TKI 
osimertinib (7). None of the pivotal EGFR-TKI trials on 
which approval was based for these EGFR-TKIs, mandated 
baseline CNS metastases screening. In the EURTAC trial 
(comparing erlotinib to platinum/gemcitabine or platinum/
docetaxel as first line treatment) (25), LUX-Lung 3 trial 
(comparing afatinib to cisplatin/pemetrexed) (26), LUX-
Lung 7 trial (comparing afatinib to gefitinib) (27), AURA 
trial (comparing osimertinib to platinum-pemetrexed) (28) 
and FLAURA trial (comparing osimertinib to standard 
EGFR-TKI) (13) only asymptomatic stable BM were 
eligible. In the ARCHER trial (comparing dacomitinib 
to gefitinib as first line treatment) patients with known 
BM were excluded (29). The presence of BM was a 
stratification factor in the LUX-Lung 7, AURA and 
FLAURA trials (13,27,28). BM specific outcomes were 
also reported for those three trials, with osimertinib having 
the highest intracranial objective response rate (icORR) 
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and intracranial progression free survival (icPFS). None 
of the trials specified whether it was allowed to administer 
local treatment in a CNS oligoprogressive patient with 
continuation of the study drug. Detailed trial description 
and results are summarized in Table 1.
Translocation of the anaplastic lymphoma kinase gene
The incidence of ALK translocation in NSCLC patients is 
about 3–7% (32,33). The incidence of BM is about 20–40% 
at baseline (34-37). Under treatment with crizotinib, the 
first approved ALK-TKI, 51–72% of patients developed 
BM. This high percentage can be explained by the poor 
CNS penetration of this drug (1,38,39). 
After crizotinib, several other next-generation ALK-
TKIs were approved, namely ceritinib, alectinib, brigatinib 
and lorlatinib (34-36,40).
Compared to EGFR-TKI trials, most ALK-TKI trials 
have intracranial responses as one of their endpoints.
A retrospective pooled analyses of the PROFILE 1005 
and PROFILE 1007 trials (respectively a single arm phase 
II trial investigating the efficacy of crizotinib in previously 
treated ALK rearranged NSCLC patients and a randomized 
phase III trial comparing crizotinib with chemotherapy 
in the same group of patients), showed that the CNS was 
the most common site of progression when on crizotinib 
treatment. Both trials included patients with asymptomatic 
or treated BM (pooled analysis: 31% with baseline BM 
of which 40% no prior brain irradiation), and baseline 
screening for BM was mandatory. In patients without BM 
at the start of crizotinib therapy 20% developed BM, with a 
median time to detection of 29.9 weeks. Next to this, CNS 
progression occurred in about 70% of patients that had 
baseline BM (20). 
In contrast to the randomized phase III EGFR-TKI 
trials, the PROFILE 1007 and 1014, the ASCEND-4 and 
5 trial, ALTA-1L trial, ALUR trial, ALEX trial as well 
as the lorlatinib trial mandated baseline CNS screening 
(34-37,41-43). In all of these trials, asymptomatic stable 
BM were eligible (34-37,40-43). Only in the PROFILE 
1014 and in the ALUR trial the BM had to be locally 
treated. BM was a stratification factor in the eight 
studies mentioned above. For all these trials, BM specific 
outcomes were reported with brigatinib having the highest 
icORR (83%). Patients with CNS only progression in the 
ALTA-1L trial, requiring local therapy such as stereotactic 
radiotherapy (SRT), were allowed to continue brigatinib 
after SRT (brigatinib mandatory paused during SRT) 
after discussion with the sponsor. Other trials did not 
allow local treatment for oligoprogression with afterwards 
continuation of the study drug. Detailed trial description 
and results are summarized in Table 2.
Other molecular alterations; ROS1, MET, RET, NTRK, 
BRAF V600E
ROS1 rearrangements occur in approximately 1–2% of 
NSCLC patients. Compared with ALK rearrangements, 
patients with ROS1 rearrangements have a lower percentage 
of baseline BM (19% vs. 39%). ROS1-positive patients also 
had a significantly lower cumulative incidence of BM (34% 
vs. 73% at 5 years). However, these are retrospective data 
without mandatory CNS metastases screening at baseline or 
standardized follow up imaging (44). 
In a phase I–II trial analysing the efficacy of lorlatinib 
in treatment naive as well as pretreated NSCLC patients 
with a ROS1 alteration (N=69), 57% of patients had BM at 
baseline. Screening for BM with MRI brain at baseline was 
mandatory. Asymptomatic treated BM, untreated BM as 
well as asymptomatic LM were eligible. The icOR was 64% 
in treatment naive patients and 50% in pretreated patients 
with crizotinib (45).
MET  de regu la t ion  [ ampl i f i c a t ion  or  exon  14 
(METex14) skipping] is found in approximately 3–4% of 
NSCLC (46). The incidence of BM in this group is about 
20% at baseline (47). 
In a phase II trial analysing the efficacy of crizotinib 
in pretreated NSCLC patients with a ROS1 alteration 
or a MET deregulation (amplification or MET exon 14 
mutations) 23% and 19% of patients had BM at baseline, 
respectively. Only patients with stable and treated BM 
were allowed. BM was not a stratification factor nor was 
BM specific outcome a prespecified endpoint. None of 
the MET+ patients with BM responded (48). Results from 
another phase II trial analysing the efficacy of capmatinib 
in pretreated as well as in treatment naive NSCLC patients 
with a MET exon 14 skipping mutation are promising, with 
intracranial response observed in 54% (7/13) of patients 
with BM at baseline. However, more data are awaited (49).
BRAF-V600E mutation is present in 1–2% of NSCLC. 
In the open label phase II trial analysing the efficacy of 
dabrafenib/trametinib in pretreated stage IV NSCLC 
patients with a BRAF-V600E mutation, 1.8% of patients 
had BM at baseline. Of note, it was not mentioned whether 
screening for BM was mandatory. Asymptomatic or treated 
BM were eligible (50). In the same study an extra cohort 
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Rosell et al. 2012, (25)
Phase III 
RCT
First line erlotinib vs. 
cis- or carboplatin with 
gemcitabine or docetaxel
NR Asymptomatic stable 11.6% (20/173) 
(erlotinib 10%, 
chemotherapy 13%)
No/no NR No (PD: study discontinuation) –
IPASS (NCT00322452), 
Mok et al. 2009, (30)
Phase III 
RCT
First line gefitinib vs. 
carboplatin-paclitaxel
NR NR NR No/no NR No (PD: study discontinuation) –
ARCHER 1050 




First line dacomitinib vs. 
gefitinib
NR All BM and LM excluded – No/no NR No (PD: study discontinuation –
LUX-lung 3 
(NCT00949650), Sequist  
et al. 2013, (26)
Phase III 
RCT
First line afatinib vs. 
cisplatin-pemetrexed
If clinically indicated 
CT/MRI brain
Asymptomatic stable BM allowed 
(stable <4 weeks and/or symptomatic 
and/or requiring treatment with 
anticonvulsants or steroids and/or LM 
disease excluded)
NR No/no CT/MRI brain 
if BM + Q6W
No (PD: study discontinuation, treatment beyond 








First line afatinib vs. 
gefitinib
NR Asymptomatic and stable BM 
(symptomatic and/or requiring 
treatment at the time of screening 
exclusion. LM exclusion)
15.7% (50/319) 




BM presence vs. 
absence)
NR No (PD: study discontinuation, treatment beyond 
radiological progression was allowed in the case of 
continued clinical benefit)
Median PFS in months (BM group): afatinib 
7.2, gefitinib 7.4 [HR 0.76 (0.41–1.44)]; 
median TTF in months (BM group): afatinib 
8.4, gefitinib 9.3 [HR 1.14 (0.64–2.03)]
AURA (NCT02151981), 
Mok et al. 2017, (28)
Phase III 
RCT
Second line osimertinib 
vs. cis- or carboplatin/
pemetrexed
Only in patients with 
known or suspected 
CNS metastases with 
CT/MRI Brain
Asymptomatic and stable BM (stable 
<4 weeks and/or symptomatic 
and/or requiring treatment with 








if BM+ Q6W 
No (PD: study discontinuation, trial treatment allowed 
beyond progression if clinical benefit)
icORR: osimertinib 70% (21/30), 
chemotherapy 31% (5/16); median icDOR: 






First line osimertinib vs. 
gefitinib or erlotinib
CT/MRI brain when 
known or suspected 
BM
Asymptomatic and stable BM 
(requiring steroids <4 weeks, when 
symptomatic but stable for at least  
4 weeks and off steroids, eligible)
21% (116/556) 
(osimertinib 19%, 







No OS HR 0.83 (CNS group) vs. 0.79 (no-CNS 
group)
CNS, central nervous system; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; BM, brain metastases; PD, progressive disease; RCT, randomised controlled trial; NR, not reported; LM, leptomeningeal metastases; CT, computer tomography; MRI, magnetic resonance imaging; Q6W, 
every 6 weeks; ic, intracranial; PFS, progression free survival; HR, hazard ratio; TTF, time to treatment failure; ORR, overall response rate; DOR, duration of response; OS, overall survival.





























Stable treated BM or asymptomatic untreated 
BM







Q6W if BM 
at baseline








Solomon et al. 2014, (37)
Phase III 
RCT






Treated BM (if neurologically stable >2 
weeks before enrollment and no ongoing 
requirement for glucocorticoids) eligible










No (PD: study 
discontinuation. 
Treatment continuation if 
clinical benefit)
PFS HR: BM 0.57 (BM present) vs. 0.46 (BM absent) in favour of 
crizotinib
Table 2 (continued)
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(NCT0182809), Soria  
et al. 2017, (36)
Phase III 
RCT
First line ceritinib vs. 
cis- or carboplatin/
pemetrexed
Brain CT or 
MRI
Asymptomatic or stable CNS metastases 
eligible (neurologically unstable or has 
required increasing doses of steroids within 
the 2 weeks prior to screening exclusion)
32% (121/376) (31% 
crizotinib, 33% 
chemotherapy)






No not allowed Ceritinib BM group: 48% (15/31) icPD only, 42% extracranial PD only 
and 10% both. Ceritinib no BM group: 30% (24/81) icPD only, 69% 
extracranial PD only, 1% both. Median PFS in months in BM group 10.7 
(ceritinib) vs. 6.7 (chemotherapy), icORR 46.3%
ASCEND-5 
(NCT01828112), Shaw 








Brain CT or 
MRI 
Asymptomatic or stable CNS metastases 
eligible (neurologically unstable or has 
required increasing doses of steroids within 
the 2 weeks prior to screening exclusion)
58% (134/231) 
(57% ceritinib, 59% 
chemotherapy)





– Median PFS in months in BM group: 4.4 ceritinib, 1.5 chemotherapy. 
68% had PD, 51% icPD only (21/41), 41% extracranial PD only, 7% 
both. In no BM group: 62% had PD. 15% icPD only, 85% extracranial 
PD only. 35% icOR. median icDOR 6.9 months
Lorlatinib 
(NCT01970865), 
Solomon et al. 2018, (40)
Phase II First, or next line 
lorlatinib
MRI of the 
brain 
Asymptomatic CNS metastases (including 
patients controlled with stable or decreasing 
steroid use within the last 2 weeks before 
study entry) LM eligible 
60% (166/275) [Group 1 
treatment naive ALK+ 8/30 
(27%). Group 2–5 ALK+ 





endpoint: icDOR, CSF 
concentration lorlatinib, 




No (PD: treatment 
discontinuation. 
Continuation if clinical 
benefit allowed)
IcORR group 1: 66.7%, group 2–5: 63%. Median time to first ic response 




Camidge et al. 2018, (35)
Phase III 
RCT
First line brigatinib vs. 
crizotinib
MRI of the 
brain  
Treated or neurologically stable for 7 days 
before randomization (symptomatic CNS 
metastases (BM or LM) at screening or 
asymptomatic disease requiring an increasing 
dose of corticosteroids <7 days prior to 
randomization exclusion)
29.5% (81/275) [Brigatinib 









Patients with CNS 
lesions requiring local 
radiotherapy such as SRS 
are allowed to continue 
the study drug after 
appropriate interruption
IcORR: brigatinib 83%, crizotinib 33%. 12-month survival without icPD in 
BM group: brigatinib 67%, crizotinib 21%
ALUR (NCT02604342), 












Asymptomatic or clinically stable treated 
CNS or LM








– PFS BM group in months: 9.7 (alectinib) vs. 1.4 (chemotherapy), icORR 
41.9%, icDCR 83.7%
ALEX (NCT02075840), 
Peters et al. 2017, (34)
Phase III 
RCT
Alectinib vs. crizotinib CT/MRI 
brain
Treated/untreated BM eligible. Previous CNS 
RT allowed if completed ≥14 days before 
enrollment
40.3% (122/303) [Alectinib 
64/152 (42.1%), Crizotinib 
58/151 (38.4%)]
CNS efficacy endpoints 








No Patients BM group: CNS progression without prior non-CNS PD 
crizotinib 56.9%, alectinib 18.8%; non-CNS progression without prior 
CNS PD crizotinib 24.1% alectinib 17.2%; death without prior CNS or 
non-CNS PD crizotinib 6.9% Alectinib 10.9%. Patients no BM group: 
CNS progression without prior non-CNS PD crizotinib 37.6% alectinib 
6.8%; non-CNS progression without prior CNS PD crizotinib 20.4% 
alectinib 28.4%; death without prior CNS or non-CNS PD crizotinib 5.4% 
alectinib 4.5%
CNS, central nervous system; ALK, anaplastic-lymphoma-kinase; TKI, tyrosine kinase inhibitor; BM, brain metastases; PD, progressive disease; RCT, randomised controlled trial; NR, not reported; CT, computer tomography; MRI, magnetic resonance imaging; Q6W, every 6 weeks; Q8W, every 8 weeks; 
Q12W, every 12 weeks; ic, intracranial; PFS, progression free survival; HR, hazard ratio; ORR, overall response rate; DOR, duration of response; DCR, disease control rate.
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was analysed with NSCLC BRAF-V600E treatment naive 
patients, 5.6% of patients had BM at baseline (51). BM 
specific outcome was not a prespecified endpoint. The 
3 included patients with BM had stable disease as best 
intracranial response (51,52). 
NTRK rearrangements occur in up to 3% of NSCLC 
patients (53). In the entrectinib phase 1 and 2 trial, 22% 
of patients had BM at baseline with a mandatory baseline 
BM screening. Patients with stable asymptomatic BM 
were eligible. IcORR, icDOR, icPFS were prespecified 
secondary endpoints (54). The larotrectinib phase I and II 
trials showed an 8% incidence of BM at baseline. However, 
screening for CNS metastases at baseline was not mandatory 
and the group of patients consisted of a heterogeneous 
population of solid tumours including pediatric patients. 
Patients with asymptomatic treated and untreated BM were 
eligible. Of the three patients with measurable baseline BM, 
one had icCR, one icPR and one icSD (55). 
RET rearrangements occur in 1–2% of NSCLC patients. 
Incidence of BM in RET-rearranged NSCLC at baseline 
is 25%, with a lifetime incidence of 46%. CNS metastases 
seem to have a good response to treatment with pralsetinib 
and selpercatinib however, data is still very limited and 
more extensive data will follow (56,57). 
Detailed trial description and results are summarized in 
Table 3.
Oligometastatic disease
Different types of oligometastatic disease exist. All are 
relevant in the treatment of patients with an oncogenic 
driver and CNS metastases. The different types of 
oligometastases are summarized below, and put into context 
regarding CNS oligometastatic disease in patients with an 
oncogenic driver. 
Oligometastatic disease is defined as a limited number 
of metastases. Two small randomized clinical trials showed 
improved survival when radical local therapy was added to 
standard systemic therapy for synchronous oligometastatic 
NSCLC, not progressing on induction systemic treatment 
(58,59). Different types of oligometastatic disease 
(e.g., synchronous, metachronous, oligopersistent, 
oligoprogressive) could represent different prognoses 
and possibly also different treatment scenarios. Recently, 
the European Society for Radiotherapy and Oncology 
(ESTRO) together with the European Organisation for 
Research and Treatment of Cancer (EORTC) developed 
a proposal for characterization and classification of 
oligometastatic disease (60). Furthermore, the EORTC 
lung cancer group provided a detailed definition plus 
staging consensus for synchronous oligometastatic 
NSCLC (61).
De novo oligometastatic disease (first time diagnosis 
of oligometastatic disease) can be defined as synchronous 
oligometastatic disease (≤6 months between primary 
cancer diagnosis and oligometastatic disease diagnosis) or 
metachronous oligometastatic disease (>6 months between 
primary cancer diagnosis and oligometastatic disease 
diagnosis). 
Synchronous and metachronous CNS oligometastases in 
patients with an oncogenic driver 
To the best of our knowledge, there is very limited data on 
the percentage of patients with an oncogenic driver and 
synchronous or metachronous CNS oligometastases. A 
phase III randomised controlled trial (RCT), comparing 
first line gefitinib to gefitinib with pemetrexed-carboplatin 
in EGFR mutated NSCLC patients showed that 4.3% 
of enrolled patients had oligometastases to the brain at 
baseline. However, this study had no mandatory screening 
of the CNS at baseline and the true percentage of CNS 
oligometastatic patients is not known (62). Most data are 
derived from CNS oligoprogression during TKI treatment, 
as is discussed below. 
CNS oligoprogression during TKI treatment
Oligoprogres s ion  i s  de f ined  a s  deve lopment  o f 
metachronous oligometastatic disease in patients under 
active systemic treatment. This type of oligometastatic 
disease is mainly prevalent in patients with oncogene 
driven NSCLC treated with targeted therapy. For TKIs 
with poor CNS penetration, oligometastatic disease in 
the brain is found in up to 38% of patients. In a post hoc 
analysis of the PROFILE 1014 trial intracranial progression 
without extracranial progression in the intention to treat 
population occurred in 24% of crizotinib patients and 10% 
of chemotherapy patients. This was in patients with treated 
BM respectively 38% vs. 23% and in patients without BM 
19% vs. 6% (63). In a retrospective series of 21 crizotinib-
treated patients, 38% developed oligoprogression in 
the brain without extracranial progression (64). In the 
ASCEND-4 trial 48% of the patients with baseline BM 
had CNS progression as first site of progression, compared 
with 30% in the group without baseline BM. It was not 
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In- or exclusion % included BM





continues in study 
(yes/no)
Results
Lorlatinib (NCT01970865), Shaw 
et al. 2019, (45)
Phase I-II
(ROS1 alteration)
Lorlatinib in treatment naive patients, disease 
progression after at least 1 ROS1 inhibitor 
therapy or any number of previous therapies 
MRI brain Asymptomatic treated or 
untreated CNS metastases 
eligible. Asymp LM eligible
57% (39/69) Primary objective ic tumour 
response; secondary 









Ic responses: TKI naive; 11 pts with baseline BM. 
45% CR, 18% PR, 18% SD, 18% PD. Previous 
treatment with crizotinib only; 24 pts with baseline 
BM. 38% CR, 13% PR, 25% SD, 8% PD
METROS (NCT02499614), Landi 
et al. 2019, (48)
Phase II
(ROS1 or MET 
alterations)





No Baseline BM: 6 ROS1; 2 CR, 4 SD, 3 only 
intracranial PD (50%). 5 MET; 2 PD, 3 SD
Dabrafenib/trametinib 




Dabrafenib plus trametinib in previously 
treated patients
NR Asymptomatic, untreated, 
measured <1 cm eligible. 
Treated BM, clinically and 
radiologically stable 3 weeks 
after local therapy
1.8% (1/57) No/no NR No ic response: SD. No patients with new BM as part 
of their progression
Dabrafenib/trametinib 




Dabrafenib plus trametinib after previously 
untreated patients
NR Asymptomatic, untreated, 
measured <1 cm eligible. 
Treated BM, clinically and 
radiologically stable 3 weeks 
after local therapy
5.6% (2/36) No/no NR No IC response: SD
Entrectinib (NCT02097810, 
NCT02568267, EudraCT 2012-
000148-88), Doebele et al. 2020, 
(54)
Phase I and II 
(NTRK)
Entrectinib in previous treated solid tumours MRI or CT Controlled asymptomatic CNS 
involvement allowed
22% (12/54) Secondary endpoints: ic 




No BM at baseline group: 6/12 (50%) PR, 4/12 (33%) 




Hong et al. 2020, (55) 
Phase I and II 
(NTRK)
Larotrectinib in previous treated solid tumours No Asymptomatic treated and 
untreated BM
8% (13/159) (6/13 
lung)











ORR in baseline BM group 75%. 3/12 patients with 
BM measurable disease. Of these 1 icCR, 1 icPR, 1 
icSD
ROS1, ROS proto-oncogene 1; MET, amplification or MET exon 14 mutations; BRAF V600E, B-Raf proto-oncogene; NTRK, N tropomyosin receptor kinase; CNS, central nervous system; TKI, tyrosine kinase inhibitor; BM, brain metastases; LM, leptomeningeal metastases; NR, not reported; CT, computer 
tomography; MRI, magnetic resonance imaging; ic, intracranial; PD, progressive disease; CR, complete remission; PR, partial remission; SD, stabile disease; Q6W, every 6 weeks; Q8W, every 8 weeks; OR, overall response; DOR, duration of response; PFS, progression free survival; ORR, overall response 
rate.
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reported if there was a difference between patients with or 
without previously radiotherapy to the brain (36). In the 
ASCEND-5 trial 51% of the patients with baseline BM had 
intracranial progressive disease as first site of progression 
compared with 15% in the group without baseline BM (42). 
A retrospective Swiss cohort study analysing 50 EGFR 
T790M-positive NSCLC patients treated with osimertinib 
showed that 17% of patients progressed in the brain 
of whom 83% had oligoprogression (65). Similar data 
were reported for the FLAURA trial, in which 13% of 
osimertinib treated patients developed oligoprogression 
to the brain only (abstract only data). In the ALEX trial, 
CNS only progression (without non-CNS progression, 
analysed with a competing risk analysis) was significantly 
less frequent at 12 months in the alectinib arm compared 
with the crizotinib arm, both in radiotherapy pretreated 
BM as well as untreated BM (8.6% vs. 50.4%, and 20.5% 
vs. 62.5%, respectively (66). Similar results were found for 
brigatinib in the ALTA-1L trial. The 1-year cumulative 
incidence of intracranial progression without prior systemic 
progression for brigatinib vs. crizotinib was 12% (95% CI, 
6–20%) vs. 23% (95% CI, 15–31%), respectively (35).  
CNS oligopersistent disease
The last subtype of oligometastatic disease is oligopersistent 
d i s e a s e ,  r e f l e c t i n g  p e r s i s t e n t  n o n - p r o g r e s s i v e 
oligometastases under active systemic treatment. Data for 
oncogene driver CNS oligopersistent disease do not exist to 
the best of our knowledge.
These definitions are important because the prognosis 
and the treatment scenarios could be different between 
these entities (60). Furthermore, the underlying molecular 
mechanisms might differ between the oligometastatic 
entities.
Molecular analysis of CNS metastases
The question whether CNS metastases harbor distinct 
genetic alterations beyond those observed in primary 
tumors has not been definitively addressed. Data with 
whole-exome sequencing in 86 patient-matched BM 
(including 38 NSCLC patients) reported 53% of cases 
with potentially clinically informative alterations in BM 
that were not detected in the matched primary tumor 
sample (67). Interestingly, upon comparison of samples 
obtained from multiple different BM from the same 
patient, most anatomically distinct BM were found to 
share virtually all actionable driver alterations (29 of 30, in 
a total of seven patients) (67,68).
However, these findings have a number of technical 
limitations such as limited genomic characterisation and 
are yet to be supported by clinical evidence. On the other 
hand, overall response rate (ORR) to targeted therapies 
in molecularly defined NSCLC patients are typically 
similar in CNS and extra-CNS disease, arguing for fewer 
molecular discordances between the primary tumor and 
CNS metastases, at least for actionable mutations (18). 
Furthermore, recent insights into LM biology have 
shown that LM might have different molecular alterations 
compared to solid BM. In particular, LM have been 
found to be enriched in EGFR, MET, and tumor protein 
p53 (TP53) mutations, whereas they rarely harbor KRAS 
alterations (7.7%) compared to other solid metastases from 
NSCLC (69,70). 
In  oncogene-addic ted  NSCLC,  i so la ted  CNS 
progression is common especially in patients treated 
with 1st or 2nd generation TKIs as is described above (18). 
Although this is most likely related to insufficient 
blood-brain barrier (BBB) penetration of TKIs (71), 
the development of secondary resistance mutations or 
histologic transformation should also be considered as 
a potential cause of disease progression, as is most often 
the case for extracranial progression. The presence of 
the oncogenic driver mutation in brain vs. extracranial 
metastases or the primary tumor differs greatly across 
studies. Small case series have investigated the concordance 
of EGFR mutation status between primary tumors and 
matched CNS metastases. Discordance rates between 0 
and 32% have been reported (72). It was also shown that 
3 out of 24 patients (12.5%) with both surgically resected 
BM and primary NSCLC, had evidence of histologic 
transformation in BM (73). Genomic profiling on tissue 
obtained from a progressing lesion to detect an acquired 
resistance to any TKI is considered the gold standard to 
determine the cause of resistance to the TKI. However, 
studies have shown that analysis of CNS metastases fails in 
up to 25% of the cases (74). Furthermore, in most patients 
with isolated CNS progression obtaining a tissue biopsy 
is not expedient due to the potential risk of neurological 
complications. Circulating tumor DNA (ctDNA) has 
emerged as a minimally-invasive tool, especially in the 
case of difficult-to-biopsy lesions or insufficient tissue 
material (75,76). It is well established that oncogenic 
drivers and resistance mutations can be detected in ctDNA 
in both plasma and cerebrospinal fluid (CSF) with high 
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sensitivity and specificity (76,77). However, in case of 
oligoprogression in the CNS, the BBB might reduce 
the presence of ctDNA in the bloodstream as has been 
reported by Aldea et al. who showed that the detection 
rate of ctDNA was significantly lower in NSCLC patients 
with isolated CNS progression compared with patients 
with extra-CNS progression (52% and 84% respectively, 
P<0.00001) (78). Since classic TKI resistance mechanisms, 
i.e., the T790M-mutation in EGFR mutated NSCLC, 
develop under selective pressure of EGFR-TKI treatment 
and given the fact that the BBB reduces the penetration of 
TKIs into the CNS, it has been stated these mechanisms 
of resistance would normally not be detected in tumor 
cells from the CNS (79). Nevertheless, there are reports 
where mutation analysis was performed on malignant cells 
present in the CNS and where the T790M mutation was 
detected (80). Therefore, analysing ctDNA in the CSF 
seems to provide a valid alternative to detect genomic 
alterations of LM and CSF ctDNA may also represent the 
molecular status of intracranial lesions (81). 
CNS penetration rate TKI
Despite favourable intracranial response rates with the 
current first line EGFR- and ALK-TKIs administered in 
standard daily doses [up to 91% for osimertinib and 81% 
for alectinib, respectively (12,13)], a significant number of 
patients will still develop isolated CNS progression as is 
described above (82,83) despite significant BBB penetration. 
At present, our understanding of BBB penetrating 
capabilities of TKIs has improved considerably. The 
key molecular properties that influence the BBB are: the 
P-glycoprotein (PGP) or breast cancer resistance protein 
(BCRP) substrate nature of the TKIs, their molecular 
weight, polar surface area (PSA) and lipophilicity index 
(LogP) (84,85). 
For first generation EGFR-TKI erlotinib and gefitinib, 
the BBB permeation or diffusion rates are 2.8–5.1% and 
1.1%, respectively (21,86,87). The CSF penetration rates 
of erlotinib and gefitinib are 2.77±0.45 and 1.13±0.36, 
respectively, and CSF concentration rates are 28.7± 
16.8 and 3.7±1.9 ng/mL, respectively (87-89). Hence, 
compared to gefitinib, the pharmacokinetic parameters 
of erlotinib appear more favourable. There is preclinical 
evidence that afatinib is an effective treatment for CNS 
metastases despite incomplete penetration of the BBB 
(27,90) even after resistance to erlotinib or gefitinib has 
developed (91). Nevertheless, in LUX-LUNG 7 the 
magnitude of PFS improvement with afatinib vs. gefitinib 
was similar to that observed in patients with or without 
BM (31). For dacomitinib, another second-generation 
EGFR-TKI, clinical data on the effect on CNS metastasis 
is not well known since these patients were specifically 
excluded from the ARCHER 1050 study (29) and another 
study of dacomitinib in patients with progressive BM 
(NCT02047747) was terminated early. 
Although the third generation EGFR-TKI osimertinib 
is a substrate for both PGP and BCRP efflux transporters, 
in vitro data have shown that unlike other EGFR-TKIs, the 
penetration rate of osimertinib is sufficient to overcome 
this efflux (92). Preclinical evidence in nonhuman primates 
shows that osimertinib has greater penetration of the BBB 
and higher brain exposure compared with other EGFR-
TKIs (92). In a PET study of healthy human volunteers, a 
single microdose of [11C]osimertinib demonstrated rapid 
and widespread distribution in the brain (93).
CSF penetration rate for crizotinib is only 0.0026% (19). 
For pat ients  with ALK-rearranged NSCLC, next 
generation ALK inhibitors were designed to cross the 
BBB more efficiently than crizotinib and to achieve higher 
concentration in the CSF, thus offering a prominent ability 
to control CNS spread. This effect was accomplished by 
reduction of their molecular weight, increasing lipophilicity 
and changing the number of available hydrogen bond 
donors. Next generation ALK-TKI are therefore more 
promising in the treatment of BM. CSF penetration rate 
for second generation ALK-TKIs alectinib and ceritinib 
are 87% and 15%, respectively (19). Paired CSF and 
systemic plasma samples analysis for alectinib demonstrated 
the linear relationship between CSF and free alectinib 
plasma concentrations (94). Brain responses have also been 
described after progression on crizotinib (95). The phase 
II ASCEND-7 study showed that ceritinib was active 
in ALK-positive patients with BM and LM regardless 
of prior treatment that included brain radiotherapy and 
prior ALK inhibitor therapy, radiotherapy alone, or 
prior sole ALK inhibitor therapy (96). Moreover, the 
selective, potent, brain-penetrant 3rd-generation ALK-
TKI lorlatinib showed clinically meaningful antitumor 
activity in both intracranial and extracranial compartments, 
in the post 2nd-gen ALK-TKI setting. Despite the 
development of TKIs with better penetration of the BBB, 
progression or the development of CNS metastases still 
occurs frequently. To increase the permeability and CSF 
concentrations of TKIs, their administration in “pulsatile” 
high-doses has been investigated (97,98). Furthermore, 
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because of oral administration of TKIs, the intrapatient 
and interpatient exposure is highly variable and is affected 
by many factors, such as concomitant use of food and 
herbs. Food-drug interactions are capable of altering the 
systemic bioavailability and pharmacokinetics (PK) of these 
drugs (99). Therefore, in suboptimally dosed patients, 
increasing the maximum concentration of drug in 
plasma blood and the CNS, e.g., dosing with food (99) 
or combining with other drugs such as proton pump 
inhibitors (100) might be necessary. Last, in patients with 
suboptimal TKI concentrations, therapeutic adherence 
should be evaluated, and if necessary, new instructions 
should be given.
Treatment options of CNS oligoprogression
Clinical controversies in the optimal management of 
oligoprogressive disease, especially CNS oligoprogression, 
remain due to a lack of prospective data comparing different 
treatment strategies (101). Furthermore, as is described 
above, a clear definition of oligometastatic disease has only 
been proposed recently (60). Whether to treat disease with 
a change of systemic therapies or to offer local ablative 
treatment [i.e., most often stereotactic radiosurgery/
therapy (SRS/SRT), if possible] is still a matter of debate. 
Ablative treatments are able to effectively target resistant 
clones regardless of the mutational genotype or load. 
Therefore, this may be an attractive additional treatment 
option for patients presenting with oligoprogression before 
considering a change in systemic treatment. In practice, 
the conventional approach to patients presenting with 
oligoprogressive disease varies depending on a number 
of patient factors including the site of oligoprogression, 
the number, size and location of the CNS metastases (i.e., 
option to offer local ablative therapy) and of course the type 
(BBB penetration or not) and number of subsequent lines of 
systemic treatments available.
Recently, the response assessment in neuro-oncology 
(RANO)-BM working group has made a framework for the 
conduction and evaluation of clinical trials for patients in 
the context of CNS metastases in order to generate more 
robust data on CNS activity than it has in the past (101). It 
is important to use bicompartmental efficacy assessments, 
specific protocol wording to record best overall, best CNS, 
and best systemic responses and duration of benefit, and to 
clarify permitted actions at CNS progression vs. non-CNS 
progression (102).
Local treatment options (radiotherapy/surgery)
Local treatment options for BM consist of whole-brain 
radiotherapy (WBRT), SRS/SRT (further described as 
SRT) or surgical resection. These treatments can relieve 
intracranial symptoms and improve intracranial local 
control. However, all of these treatments have a risk of 
neurotoxicity, which can occur months after treatment 
(e.g., symptomatic radiation necrosis after SRT, cognitive 
decline after WBRT) (103,104). Therefore, especially 
WBRT with its late neurocognitive toxicity is being more 
and more avoided in patient with an oncogenic driver. 
Surgery is usually only used in case of a patient with 
neurological symptoms due to mass effect. Surgery would 
also be interesting to evaluate CNS resistance mechanisms 
in patients with CNS oligoprogression while on TKI 
treatment. To the best of our knowledge, no high-level data 
exist on this topic. 
 Furthermore, for each patient with CNS metastases, 
the risk-benefit ratio of local therapy, and the alternative 
of systemic treatment with CNS efficacy should be 
evaluated (i.e., alectinib after progression on crizotinib 
in ALK-rearranged NSCLC patients or osimertinib after 
progression on erlotinib in EGFR-mutated NSCLC patients 
with a T790M mutation) , taking into account the expected 
long term OS. 
Broadly speaking, three situations can occur in driver 
mutated patients with CNS metastases eligible for a TKI. 
The first is a treatment naive patient with CNS metastases. 
The second is a patient treated with a TKI, developing 
oligoprogression in the brain. The last is a patient who 
develops simultaneous CNS and extra-CNS progression 
under TKI treatment.  
By giving upfront TKIs and postponing radiotherapy 
to a TKI naive patient, the possible neurotoxicity could 
be delayed, which is important because of the increasing 
survival in this patient group. Furthermore, by upfront 
TKI, the extracranial disease will be controlled as early as 
possible. However, icORR is not 100%, and patients can 
develop neurological symptoms due to their progressing 
CNS metastases. A multi-institutional retrospective 
analysis including EGFR-mutated NSCLC, TKI naive 
patients who developed BM, demonstrated that the use 
of upfront EGFR-TKI, and deferral of radiotherapy was 
associated with inferior OS. SRT followed by EGFR-
TKI resulted in the longest survival. However, this 
study is limited by its retrospective nature with inherent 
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selection bias (94). A systematic review and meta-analysis 
evaluated whether upfront cranial radiotherapy improved 
intracranial disease control and survival in EGFR-mutant 
NSCLC with BM compared with TKIs alone. The study 
included 12 observational non-comparative studies, of 
which 6 prospective and 6 retrospective. Upfront cranial 
radiotherapy resulted in similar icORR, improved four-
month icPFS and improved two-year OS, but caused 
more neurological adverse events compared with TKIs 
alone (105). To complicate matters, preclinical studies 
demonstrate a possible synergistic effect of TKIs given 
concurrently with radiation, but toxicity data of this 
concurrent strategy is largely lacking in daily clinical 
practice (106-108). A retrospective analysis showed that in 
patients with EGFR and ALK concomitant radiotherapy 
(SRT) and TKI seemed to positively affect OS with 
limited toxicity in selected patients (93). A systematic 
review concluded that there are arguments that TKI 
combined with WBRT could be given safely (however 
high-level evidence is lacking, and evidence was only found 
for erlotinib, gefitinib and icotinib, while data on other 
TKI or SRT were largely lacking) (109). When WBRT 
was given combined with SRT and concurrent EGFR-
TKI neurotoxicity increased (95). A few studies looked 
specifically at isolated intracranial oligoprogression. 
One retrospective study assessed the clinical efficacy of 
continuing an EGFR-TKI following radiotherapy after 
isolated CNS failure. The overall median PFS was 2.6 
months with a median extracranial PFS of 5.6 months. Al 
the patients were evaluated for their evaluable lesions with 
imaging approximately every 2 months (110). Another 
retrospective analysis including CNS oligoprogressive ALK 
or EGFR positive NSCLC patients treated with crizotinib 
or erlotinib respectively, investigated the benefits of local 
ablative treatment (included SRT and WBRT) to the CNS 
metastases. The median PFS (calculated from time of 
initiation of targeted therapy to first progression of disease) 
was 7.1 months (111). A retrospective study evaluated 
continuing crizotinib after radiotherapy (4 patients WBRT 
and 3 patients SRT) to isolated CNS metastases in 7 ALK 
NSCLC patients. The median PFS, from time of start 
crizotinib to first progression, was 5.5 months. All these 
patients continued to receive crizotinib for at least 4 months 
without disease progression (64). The previously mentioned 
pooled analysis of the PROFILE trials showed data of 
34 patients, developing intracranial progression only and 
continued the use of crizotinib. About 80% of these patients 
received radiotherapy. The median treatment duration post 
progression was 19.3 weeks (20). As the majority of these 
studies were retrospective, and most of them only included 
patients treated with a first generation TKI, the optimal 
treatment strategy or sequence of the combination of 
(newer) TKIs and local therapy remains unclear, especially 
in those with a non-EGFR driver. In 2018, an EORTC 
lung cancer group survey among 462 physicians, showed 
that management of CNS metastases was indeed highly 
variable in Europe, showing the lack of high-level evidence 
regarding management of CNS metastases in patients with 
an oncogenic driver (8). 
Future research should focus on the best order of 
systemic and local treatment; upfront cranial radiation 
or upfront TKI with salvage radiotherapy for oligo-
progressive CNS disease. Trials currently ongoing and 
investigating this issue are a study of osimertinib and SRT 
vs. osimertinib alone for BM in EGFR positive NSCLC 
patients (NCT03769103); The OUTRUN trial, a phase 
II trial of osimertinib with or without SRT for EGFR 
positive NSCLC patients with BM (NCT03497767); the 
BRART trial, investigating the role of brain radiotherapy 
in patients with asymptomatic BM in the era of targeted 
therapy for NSCLC (NCT04193007); a phase III RCT 
investigating the efficacy of EGFR-TKI alone in EGFR-
positive NSCLC patients vs. EGFR-TKI concurrent 
with WBRT (NCT02714010) and the Cambridge Brain 
Mets Trial, investigating whether administration of a low 
dose of targeted radiotherapy during afatinib treatment 
could increase the concentration of drug penetration into 
the BM (NCT02768337). Furthermore, in both TKI 
treatment naive patients with CNS disease, as in those with 
oligoprogressive CNS disease during TKI treatment the 
use of concurrent treatment strategies should be further 
evaluated. The EORTC survey of Levy et al. showed that 
depending on the type of TKI, up to 44% of physicians 
continued the TKI concurrent with cranial irradiation. 
For those discontinuing the TKI, time of, and reasons for 
discontinuation were variable (8). As these patients often 
have a long survival, long-term toxicity and QoL should be 
taken into account as well. Currently, a multicenter phase 
IV trial is ongoing, with as primary endpoint neurotoxicity, 
investigating whether TKIs can be given safely concurrent 
with SRT or WBRT in CNS oligoprogressive patients 
treated with a TKI (NTR6707). Another ongoing phase 
I trial in EGFR positive NSCLC patients with 1–10 BM 
(3 cm or less in greatest dimension) is investigating whether 
macro BM can be controlled with SRT concurrent with 
osimertinib to control micro BM and avoid WBRT to 
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prevent cognitive decline (NCT03535363).
Systemic treatment options
Although attractive in many cases, the utility of conventional 
systemic therapy in the treatment of BM has historically 
been limited due to poor penetration across the BBB and 
blood-tumor barrier (112). Traditional clinical trials for 
systemic therapies have excluded patients with symptomatic 
or uncontrolled BM due to these challenges with CNS 
penetration (113). The development of new generation 
TKI with better CNS permeability also challenges the 
concept of upfront radiotherapy for CNS metastases as 
is also described above, offering both better efficacy and 
tolerability. Moreover, in retrospective series, patients with 
EGFR mutations and ALK rearrangements who continue 
TKI beyond first progression, especially those with isolated 
CNS progression, have been suggested to have a survival 
benefit when treated with local CNS therapy, compared 
with patients who stop TKI (111,114,115). Tumour flare, 
which can occur with the interruption of TKI, again in 
particular in patients with CNS disease, may play a role in 
this (111,116). Furthermore, the third generation EGFR-
TKIs (osimertinib, rociletinib, and AZD3759) have been 
proved in preclinical and early clinical studies to penetrate 
the BBB more effectively than previous generation EGFR-
TKIs, and overcome their most common mechanisms of 
resistance (92,117). 
As mentioned before, “pulsatile” high-doses of TKI to 
increase the permeability and CSF concentrations have 
been investigated. Currently this concept is used in series 
to treat BM and LM that developed during standard dose 
EGFR-TKI. Erlotinib has better BBB penetration than 
afatinib or gefitinib, and dose-intensification strategies have 
been proven to improve CNS diffusion of TKI (87,88). 
Prospective studies have confirmed the feasibility of TKI 
dose increase in clinical practice, notably for erlotinib and 
osimertinib (98,118). In small series, high-dose EGFR-TKIs 
and switch of EGFR-TKI treatment have been described as 
treatment options. In a phase I prospective study, median 
neurological PFS and OS with high-dose gefitinib (750–
1,000 mg) were reported as 2.3 and 3.5 months, respectively 
(N=7) (119). 
Data on treatment outcomes of oncogene-addicted 
NSCLC patients diagnosed with LM during or after first 
generation TKI treatment are scarce. Several case studies 
have reported successful treatment of LM with high-
dose pulsatile administration of erlotinib (120); however, 
a retrospective study of patients with LM refractory to 
standard dose EGFR-TKIs found no difference in the 
median OS between patients treated with high-dose 
erlotinib (N=12) and those treated with standard-dose 
EGFR-TKIs (N=23; 6.2 vs. 5.9 months, respectively); 
median time to CNS progression was 2.3 months (121). In 
the BLOOM trial, a phase 1 study, the antitumor efficacy, 
PK and safety of osimertinib 160 mg once daily in patients 
with EGFR-mutated NSCLC and LM whose disease 
had progressed on previous EGFR-TKI therapy (98). 
Confirmed CSF response was observed in 28% of patients 
during treatment. However, the definition of CNS response 
was complete CSF clearance of tumor cells while more 
recent studies have defined partial CSF response as a ≥50% 
reduction in CSF tumor cells because CSF clearance is 
seldom achieved (77). Moreover, in the BLOOM study, the 
data showed no positive effect of prior brain radiotherapy 
on LM response to osimertinib. LM ORR was 55% in 
patients who received prior brain radiotherapy compared 
with 57% in patients who did not receive prior brain 
radiotherapy (98). 
Besides dose-intensification strategies, several studies 
have looked at combining EGFR-TKI with vascular 
endothelial growth factor directed monoclonal antibody 
therapy (122). The BELIEF trial was an international, 
multicenter, single-arm phase II trial of 109 treatment-
naïve, advanced or metastatic, EGFR-mutant, lung 
adenocarcinoma patients treated with the combination 
erlotinib and bevacizumab (123). Thirty-seven patients 
(34%) harbored T790M mutations and 21 (19%) had BM; 
the median PFS was 13.2 months overall and 8.8 months 
for patients with BM (123). The efficacy of this combination 
in the BM population does not appear to be superior to 
standard EGFR TKI therapy (27), however only 21 patients 
with BM were included in the BELIEF trial. One of the 
greatest concerns with bevacizumab use among brain 
metastatic patients has been CNS hemorrhage. While 
CNS hemorrhage carries high morbidity and mortality, 
the incidence of CNS hemorrhage among bevacizumab-
treated patients is less than 0.2% (124). Ongoing 
studies are investigating the combination of osimertinib 
and bevacizumab in EGFR-mutant NSCLC with BM 
(NCT02971501).
When all TKI options are exhausted, platinum-doublet 
chemotherapy is the therapy of choice (7). Intracranial 
response rates are relatively low compared with TKI (125), 
and to the best of our knowledge no data exist regarding 
intracranial efficacy of platinum-doublet chemotherapy in 
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patients with CNS oligoprogression. Up to date there is 
no evidence that combining or continuing TKI treatment 
with platinum-based chemotherapy after CNS progression 
improves intracranial response rates or OS.
Conclusions
CNS metastases are common in oncogene addicted 
NSCLC patients. Incidence increases during the course 
of the disease, especially with first generation TKI 
treatment, due to the relatively low CNS penetration 
rate. A significant percentage of TKI treated patients will 
have CNS oligoprogression, also when treated with next 
generation TKIs. Unfortunately, most clinical trials did 
not specify endpoints nor treatment options regarding 
CNS oligoprogression. Furthermore, CNS efficacy data 
in clinical trials are not fully comparable, because imaging, 
eligibility criteria and endpoints were not standardised. 
Future research is necessary to investigate the best CNS 
treatment strategy in oncogene driven patients with CNS 
metastases. This is especially the case for patients with 
CNS oligoprogression, as trial data are largely lacking, 
and data available come from retrospective series. Future 
research with standardisation of clinical trials in the context 
of CNS metastases is necessary to understand the best 
order of systemic treatment and local treatment strategies. 
Both the EORTC oligometastatic consensus papers as well 
as the RANO proposal could be of help in standardizing 
clinical trials. Last, special attention should be paid to long-
term toxicity, as the majority of oncogene driven NSCLC 
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